ITT Corporation Diaphragm Passes ASME BPE Seal Test
The valve received the highest cycle rating after completing the test at three times the required test pressure.
ITT Corporation’s Pure-Flo EnviZion hygienic diaphragm valve passed the ASME BPE 2014 Edition Appendix J testing, according to an April 13, 2016 press announcement from ITT. The EnviZion is a hygienic diaphragm valve developed for biopharmaceutical production processes.
The ASME BPE Standard was established in 1997 and cGMPs for the design of equipment for the production of biopharmaceuticals. SG Sealing Components subcommittee of ASME published Appendix J as a set of standard process test conditions for seal performance including diaphragm valve diaphragms, ITT said in a press announcement.
According to ITT Corporation, the ASME BPE 2014 Edition Appendix J test provided validation of the integrity and liability of EnviZion valve’s live thermal cycle compensation system. The valve received maximum cycle rating from ASME, after it completed the test at three times the required test pressure, ITT said.
Source: ITT Corporation
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
